Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors

This publication has 14 references indexed in Scilit:

• Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
  British Journal of Cancer, 1996
• Detection of platinum-DNA adducts by³²P-postlabelling
  Nucleic Acids Research, 1995
• Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
  Biochemical Pharmacology, 1994
• Cisplatin resistance in human cancers
  Pharmacology & Therapeutics, 1991
• Platinum—DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry
  Carcinogenesis: Integrative Cancer Research, 1991
• 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase
  Journal of Medicinal Chemistry, 1991
• The measurement of cisplatin-DNA adduct levels in testicular cancer patients
  Carcinogenesis: Integrative Cancer Research, 1988
• Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosides
  The Journal of Organic Chemistry, 1988
• Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
  Journal of Clinical Investigation, 1986
• Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation
  Biochemistry, 1985